Clinical Trial Detail

NCT ID NCT03434379
Title A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150]
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Hoffmann-La Roche
Indications

hepatocellular carcinoma

Therapies

Atezolizumab + Bevacizumab

Sorafenib

Age Groups: senior adult

No variant requirements are available.